Union Hospital, Tongji Medical College,Huazhong University of Science and Technology;
Welcome,         Profile    Billing    Logout  
 0 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yang, Kun-Yu
DIPPER, NCT03427827: PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

Active, not recruiting
3
450
RoW
Camrelizumab, SHR-1210
Sun Yat-sen University
Nasopharyngeal Neoplasms
02/24
02/26
NCT06749899: QL1706 (IPD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Recruiting
3
580
RoW
QL1706, Gemcitabine, Cisplatin, Intensity-modulated radiotherapy
Sun Yat-sen University, Qilu Pharmaceutical Co., Ltd.
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
12/28
12/30
AK104-IIT-019, NCT05587374: Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma

Recruiting
3
418
RoW
Cadonilimab, PD-1/CTLA-4 bi-specific antibody, Gemcitabine, GEM, Cisplatin, DDP, Intensity-modulated radiotherapy, IMRT
Sun Yat-sen University, Akeso Pharmaceuticals, Inc.
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
01/25
01/27
DIAMOND, NCT04907370: PD-1 Blockade Combined With De-intensification Radical Chemoradiotherapy in Nasopharyngeal Carcinoma

Active, not recruiting
3
540
RoW
PD-1 blocking antibody, PD-1 Blockade, Gemcitabine, GEM, Cisplatin (80mg/m2), DDP, Cisplatin (100mg/m2), Intensity-modulated radiotherapy, IMRT
Sun Yat-sen University, Shanghai Junshi Bioscience Co., Ltd.
Nasopharyngeal Carcinoma
05/25
05/27
NCT05979961: Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

Recruiting
3
454
RoW
IMRT and concurrent cisplatin, gemcitabine and cisplatin (Induction chemotherapy)
Sun Yat-sen University, First Affiliated Hospital of Guangxi Medical University, Zhongshan People's Hospital, Guangdong, China, Wuhan Union Hospital, China, Tongji Hospital, Guangzhou Panyu Central Hospital, Hunan Cancer Hospital, Cancer Hospital of Guizhou Province
Nasopharyngeal Carcinoma
09/26
09/29
PLATINUM, NCT03984357: Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma

Active, not recruiting
2
152
RoW
PD-1 blocking antibody, PD-1 blockade, Gemcitabine, GEM, Cisplatin, DDP, Intensity-modulated radiotherapy, IMRT
Sun Yat-sen University, Bristol-Myers Squibb
Nasopharyngeal Carcinoma
04/24
03/26

Download Options